Research Index
Sermorelin Research Index
PSI surfaces 50 peer-reviewed studies on Sermorelin, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
Coutinho LFD, DE Oliveira Neves LF, Camilo RP
J Sports Med Phys Fitness·2026·Animal·PubMed →
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
Uçaktürk E, Nemutlu E
J Pharm Biomed Anal·2026·Animal·GH Activity·PubMed →
Growth hormone - releasing hormone antagonists induce autophagy in cancer cells.
Sigdel M, Fakir S, Sarker MMR et al.
Growth Horm IGF Res·2025·Animal·GH Activity·PubMed →
Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
Gesmundo I, Pedrolli F, Giglioli FR et al.
Int J Mol Sci·2025·Animal·GH Activity·PubMed →
Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers.
Muñoz-Moreno L, Gómez-Calcerrada MI, Arenas MI et al.
Int J Mol Sci·2024·Animal·GH Activity·PubMed →
Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.
Gaumond SI, Abdin R, Costoya J et al.
Oncotarget·2024·Animal·GH Activity·PubMed →
Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Thomas A, Walpurgis K, Thevis M
J Mass Spectrom·2024·Animal·GH Activity·PubMed →
Growth hormone-releasing hormone receptor antagonist MIA-602 attenuates cardiopulmonary injury induced by BSL-2 rVSV-SARS-CoV-2 in hACE2 mice.
Condor Capcha JM, Kamiar A, Robleto E et al.
Proc Natl Acad Sci U S A·2023·Animal·Anti-Inflammatory, Weight Loss·PubMed →
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.
Cristea CD, Radu M, Toboc A et al.
Anal Biochem·2023·Animal·PubMed →
In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides.
González-López NM, Guerra-Acero-Turizo LM, Blanco-Medina I et al.
Biomed Chromatogr·2023·Animal·GH Activity·PubMed →
Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.
Granato G, Gesmundo I, Pedrolli F et al.
Front Immunol·2023·Animal·GH Activity, Anti-Inflammatory·PubMed →
GHRH agonist MR-409 protects β-cells from streptozotocin-induced diabetes.
Louzada RA, Blandino-Rosano M, Flores S et al.
Proc Natl Acad Sci U S A·2023·Animal·Anti-Inflammatory·PubMed →
Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis.
Otin J, Tran NT, Benoit A et al.
Electrophoresis·2023·Animal·GH Activity·PubMed →
Probing for peptidic drugs (2-10 kDa) in doping control blood samples.
Thomas A, Thilmany S, Hofmann A et al.
Anal Sci Adv·2022·Animal·PubMed →
Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
Muñoz-Moreno L, Carmena MJ, Prieto JC et al.
Prostate·2022·Animal·GH Activity·PubMed →
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
Coppieters G, Deventer K, Polet M et al.
J Pharm Biomed Anal·2022·Animal·GH Activity·PubMed →
Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
Cai R, Zhang X, Wang H et al.
Peptides·2022·Animal·Anti-Inflammatory, GH Activity·PubMed →
Impact of growth hormone-releasing hormone antagonist on decidual stromal cell growth and apoptosis in vitro†.
Wu HM, Chen LH, Schally AV et al.
Biol Reprod·2022·Animal·GH Activity·PubMed →
A potentially effective drug for patients with recurrent glioma: sermorelin.
Chang Y, Huang R, Zhai Y et al.
Ann Transl Med·2021·Human·PubMed →
Advances in the detection of growth hormone releasing hormone synthetic analogs.
Memdouh S, Gavrilović I, Ng K et al.
Drug Test Anal·2021·Animal·GH Activity·PubMed →
Effects of growth hormone-releasing hormone receptor antagonist MIA-602 in mice with emotional disorders: a potential treatment for PTSD.
Recinella L, Chiavaroli A, Orlando G et al.
Mol Psychiatry·2021·Animal·PubMed →
Effects of growth hormone-releasing hormone agonistic analog MR-409 on insulin-secreting cells under cyclopiazonic acid-induced endoplasmic reticulum stress.
Rodrigues-Dos-Santos K, Soares GM, Guimarães DSPSF et al.
Mol Cell Endocrinol·2021·Animal·GH Activity·PubMed →
Agonist of growth hormone-releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury.
Cen LP, Ng TK, Liang JJ et al.
Proc Natl Acad Sci U S A·2021·Animal·GH Activity, Anti-Inflammatory·PubMed →
Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice.
Recinella L, Chiavaroli A, Orlando G et al.
Peptides·2021·Animal·Weight Loss, GH Activity·PubMed →
Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.
Rieger AC, Bagno LL, Salerno A et al.
Proc Natl Acad Sci U S A·2021·Animal·GH Activity·PubMed →
Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
Pont L, Alechaga É, Terrero A et al.
J Chromatogr A·2020·Animal·GH Activity·PubMed →
GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity.
Barabutis N, Akhter MS, Uddin MA et al.
Horm Metab Res·2020·Animal·GH Activity, Neuroprotection·PubMed →
A glimpse at growth hormone-releasing hormone cosmos.
Barabutis N
Clin Exp Pharmacol Physiol·2020·Animal·GH Activity·PubMed →
Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.
Xiong X, Ke X, Wang L et al.
Proc Natl Acad Sci U S A·2020·Animal·PubMed →
Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.
Liang WC, Ren JL, Yu QX et al.
Proc Natl Acad Sci U S A·2020·Animal·PubMed →
Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice.
Recinella L, Chiavaroli A, Orlando G et al.
Sci Rep·2020·Animal·PubMed →
Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
Grugni G, Marzullo P, Ragusa L et al.
Clin Endocrinol (Oxf)·2006·Human·GH Activity, Weight Loss·PubMed →
Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.
Munafo A, Nguyen TX, Papasouliotis O et al.
Eur J Endocrinol·2005·Human·GH Activity·PubMed →
Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep.
Jessup SK, Malow BA, Symons KV et al.
Eur J Endocrinol·2004·Human·GH Activity·PubMed →
The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency.
Achermann JC, Brook CG, Hindmarsh PC
Eur J Endocrinol·2000·Human·GH Activity·PubMed →
Quantitative growth hormone secretion and final adult height.
Trainer PJ, Palermo M, Kirk JM et al.
Clin Endocrinol (Oxf)·1999·Human·GH Activity·PubMed →
The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14)(SS) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals.
Achermann JC, Hindmarsh PC, Robinson IC et al.
Clin Endocrinol (Oxf)·1999·Human·PubMed →
Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.
Pandya N, DeMott-Friberg R, Bowers CY et al.
J Clin Endocrinol Metab·1998·Human·PubMed →
Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
Leal-Cerro A, Venegas E, Garcia-Pesquera F et al.
Clin Endocrinol (Oxf)·1998·Human·GH Activity·PubMed →
Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V, Simic M, Ilic L et al.
Clin Endocrinol (Oxf)·1998·Human·GH Activity·PubMed →
Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF, Hindmarsh PC, Brook CG
Clin Endocrinol (Oxf)·1997·Human·GH Activity·PubMed →
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women.
Khorram O, Yeung M, Vu L et al.
J Clin Endocrinol Metab·1997·Human·Longevity, GH Activity, Immune Modulation·PubMed →
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O, Laughlin GA, Yen SS
J Clin Endocrinol Metab·1997·Human·Longevity, GH Activity·PubMed →
Growth hormone release by the novel GH releasing peptide hexarelin in patients with homozygous beta-thalassemia.
Tolis G, Karydis I, Markousis V et al.
J Pediatr Endocrinol Metab·1997·Human·GH Activity·PubMed →
Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome.
Beccaria L, Benzi F, Sanzari A et al.
J Endocrinol Invest·1996·Human·GH Activity·PubMed →
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.
Thorner M, Rochiccioli P, Colle M et al.
J Clin Endocrinol Metab·1996·Human·GH Activity·PubMed →
Plasma GH responses to human GHRH-antagonist in normal subjects.
Hanew K, Tanaka A, Utsumi A et al.
Eur J Endocrinol·1996·Human·GH Activity·PubMed →
Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature.
Tuilpakov AN, Bulatov AA, Peterkova VA et al.
Metabolism·1995·Human·GH Activity·PubMed →
GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers.
Tiulpakov AN, Brook CG, Pringle PJ et al.
Clin Endocrinol (Oxf)·1995·Human·GH Activity·PubMed →
Low-dose growth hormone-releasing hormone tests: a dose-response study.
Spoudeas HA, Winrow AP, Hindmarsh PC et al.
Eur J Endocrinol·1994·Human·GH Activity·PubMed →